Rapid Micro Biosystems EBIT

The latest EBIT for RPID is $-49M as of June 2026. That compares with $-45M in the prior-year period — down 9.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Rapid Micro Biosystems's historical trend and sector peers before judging valuation or financial health.

Over the past year, RPID's EBIT moved from $-45M to $-49M — a 9.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rapid Micro Biosystems's operating scale or balance-sheet position.

Against Healthcare companies, RPID currently prints $-49M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Rapid Micro Biosystems's growth, margins, and balance sheet.

A EBIT figure of $-49M for RPID is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting RPID's EBIT ($-49M), review year-over-year change from $-45M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.